Nacia Pharmaceuticals

Nacia Pharmaceuticals was a private biotechnology company based in Lexington, Massachusetts, that operated on a virtual drug discovery model. The company focused on the development of small molecule inhibitors targeting Cathepsin S, a cysteine protease involved in MHC class II-mediated antigen presentation. Its primary therapeutic focus was on autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Founded by industry veterans, the company aimed to leverage a lean operational structure to advance its lead programs through early-stage development. However, the company appears to have ceased active operations in the mid-2010s.